MOONLAKE IMMUNOTHERAPEUTICS
Last · NASDAQ$10.14-0.27 (-2.59%)close · yahoo · 17h ago
Market cap$862.98M85.1M sh
P/E · TTM-2.7fwd -3.0 · eps -3.73 · loss
Beta1.08vs S&P 500
Div yield0.00%annual · TTM
52w range
$8.80$23.29
Volume1.8Msession
Loading chart…
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.78
Est. revenue
0
Press & signals
- GlobeNewswire
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
- GlobeNewswire
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
Documents
FormReporting forFiledFlags